Trauma Implant Market Size and Share
Market Definition
Implants and instruments such as plates, screws, intramedullary nails, pins, wires, staples and external fixators.
April 2025
Mike Evers, Senior Market Analyst
Welcome to our overview of the trauma market. This page builds upon and updates our trauma chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
The Market at a Glance
Trauma sales surpassed $9 billion in 2024, accounting for 15% of the $62 billion global orthopedic market. A resurgent core fracture repair market combined with the faster-growing foot and ankle segment helped trauma sales grow in the mid-single-digits in 2024.
Consolidation in the trauma market peaked around 2020, driven by an appetite for foot and ankle assets, but it still accounts for 17% of all orthopedic M&A since 2021. Trauma could see an uptick in M&A activity as the core market evolves and advances.
Market Forecast
Healthy demand, an expanding foot and ankle market and core trauma innovation led to robust growth in 2024. We project the segment will normalize toward its historical averages in the coming years, with $9.4 billion in sales in 2025 and$10.7 billion by 2028.
Favorable demographics, underserved markets and innovation will drive growth over the next few years.
Exhibit 1: Worldwide Trauma Sales by Year ($millions)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 75 public and private companies by segment from 2016 through 2024.
Here are some of the trauma market dynamics we considered in our forecast:
Demographic Tailwinds. The trauma segment benefits from longer life expectancy increased incidence of diabetes and obesity among potential patients. According to the U.S. Department of Health and Human Services, about 16% of the U.S. population is 65 or older. By 2040, that percentage will increase to 22%. According to the Centers for Disease Control and Prevention (CDC), the prevalence of diagnosed diabetes in the U.S. population increased from 0.9% in 1958 to 10.5% in 2018. Likewise, 2018 data from the CDC showed a staggering 74% of the U.S. adult population was overweight or obese.
Choppy Foot and Ankle Volumes. Surgical volumes are inconsistent in the space. The number of procedures slowed in late 2023 and remained inconsistent throughout much of 2024. We expect quarterly variability in 2025 due to the depletion of backlogged procedures and lower priority placed on foot and ankle compared to other specialties. Still, foot and ankle market sales average out to high-single-digit growth.
Opportunities for Innovation. While the core trauma segment is large and mature, the need for novel solutions remains. X-Bolt’s mechanically reversible PRO-X1 Trochanetic Nail provides a new way to treat patients with osteoporotic hip fractures. In trials, the PRO-X1 had a cut-out rate of 0.8%, less than half of the 2.5% that is typically reported in the literature. Onkos Surgical’s NanoCept Antibacterial Technology, a novel coating applied to implants to help address intraoperative bacterial contamination, could have broad applicability in oncology, trauma and revision surgeries.
Sales by Region
Volume-based procurement (VBP) in China created substantial price cuts for trauma implants in 2023 and has largely shifted off-tender volumes to domestic players. Globalized players that decided to remain in the Chinese market have adjusted their level of investment and expected return.
Several public companies reported international success elsewhere in 2024 and said they’re increasingly looking to new geographic markets to maintain healthy growth rates. Stryker called Europe “a growth engine.” Further, smaller European and Asian companies are targeting the United States and Latin American countries to increase sales.
Exhibit 2: Trauma Sales by Region ($millions)
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $5,986.3 | $5,622.8 | $363.4 | 6.5% |
| OUS | $3,083.8 | $2,909.5 | $174.3 | 6% |
| EMEA | $1,659.8 | $1,552.9 | $106.9 | 6.9% |
| APAC | $997.7 | $968.4 | $29.3 | 3% |
| ROW | $426.3 | $388.2 | $38.1 | 9.8% |
| Total | $9,070.1 | $8,532.4 | $537.7 | 6.3% |
Exhibit 3: Trauma Market Share by Region ($millions)
Top Companies
The trauma market has two players — Johnson & Johnson MedTech and Stryker — with double-digit market share. Both companies control at least 29% of the trauma market, about four times the nearest competitor.
Zimmer Biomet, Smith+Nephew and Acumed round out the top five players. Combined, this group accounts for 77% of global trauma sales. That percentage increased in early 2025 when Zimmer Biomet agreed to acquire Paragon 28.
Exhibit 4: Top 10 Trauma Players and All Others ($millions)
| Company | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| J&J MedTech | $2,713.1 | $2,651.2 | $61.9 | 2.3% |
| Stryker | $2,625.9 | $2,352.6 | $273.3 | 11.6% |
| Zimmer Biomet | $681.5 | $664.2 | $17.3 | 2.6% |
| Smith+Nephew | $530.4 | $490.0 | $40.4 | 8.3% |
| Acumed | $418.9 | $400.5 | $18.4 | 4.6% |
| Paragon 28 | $215.4 | $186.1 | $29.3 | 15.7% |
| Arthrex | $213.7 | $204.3 | $9.4 | 4.6% |
| Medartis | $213.5 | $195.0 | $18.4 | 9.4% |
| Treace Medical Concepts | $205.6 | $187.1 | $18.5 | 9.9% |
| Skeletal Dynamics | $128.8 | $118.7 | $10.1 | 8.5% |
| All Others | $1,123.3 | $1,082.6 | $40.6 | 3.8% |
| Total | $9,070.1 | $8,532.4 | $537.7 | 6.3% |
Exhibit 5: Trauma Market Share by Company ($millions)
VBP in China and portfolio gaps hampered Johnson & Johnson MedTech’s ability to drive market growth in trauma. In contrast, Stryker’s acquisition of Wright Medical provided the company with an infusion of products and executives that put it on the path to leadership in the trauma segment. Stryker’s largest-ever trauma launch, the Pangea plating system, will reach full commercialization in the second half of 2025 and spur more growth.
In the next tier of companies, Zimmer Biomet took a major step in addressing its trauma strategy with the pending acquisition of fast-growing Paragon 28. Smith+Nephew’s EVOS plating system drove strong sales in 2024, making trauma one of the few orthopedic bright spots for the company.
Among smaller players, Treace Medical faced some headwinds during 2024 but is expanding its portfolio to address a broader range of procedures. Enovis’ foot and ankle business reached the $100 million market in short order, and the company expects it to reach $200 million in the next few years.
Important Developments in the Trauma Market
Under the Radar Highlight. According to Globus Medical’s leadership, the integration of NuVasive Specialty Orthopedics’ trauma products was a highlight of the merger. The products fit with Globus Medical’s strategic goal to address a full range of musculoskeletal treatments. The combined business found increased market penetration and uptake during 2024. Supply constraints offset some growth potential in the fourth quarter, but Globus Medical believes the opportunities for its trauma business have never been stronger.
Orthofix’s Strategic Shift. Orthofix’s hectic 2023 included the integration of SeaSpine and a sudden leadership change. While the combined organization emerged from the year with solid pro forma growth, the company faced questions about its slow-growing trauma business. That business took a significant step forward in 2024, driven by a strategic shift to focus on the U.S. market, which saw sales increase 16% over 2023.
Zimmer Biomet Takes Major Step. Zimmer Biomet struggled to generate the same foot and ankle momentum as its peers. In 2023, the company said foot and ankle sales made up 4% of its S.E.T. category, or around $70 million. The company made a significant move to contend in the space when it entered into a definitive agreement to purchase Paragon 28 for a total enterprise value of $1.2 billion. The deal will boost Zimmer Biomet’s foot and ankle revenue to more than $320 million.
Further Reading
Thanks for visiting! Need more insight on the trauma market? Questions and comments are always welcome. You can reach me by email. Until then, I’ve selected a few posts that give insight into our thinking on the trauma market.
January 30, 2025
,
Mike Evers
March 19, 2025
,
Julie A. Vetalice
Our overview of the $9 billion trauma market includes up-to-date information on forecasted growth, the top companies and industry-driving trends.
Market Definition
Implants and instruments such as plates, screws, intramedullary nails, pins, wires, staples and external fixators.
April 2025
Mike Evers, Senior Market Analyst
Welcome to our overview of the trauma market. This page builds upon and updates our trauma chapter in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT®.
The Market at a Glance
Trauma sales surpassed $9 billion in 2024, accounting for 15% of the $62 billion global orthopedic market. A resurgent core fracture repair market combined with the faster-growing foot and ankle segment helped trauma sales grow in the mid-single-digits in 2024.
Consolidation in the trauma market peaked around 2020, driven by an appetite for foot and ankle assets, but it still accounts for 17% of all orthopedic M&A since 2021. Trauma could see an uptick in M&A activity as the core market evolves and advances.
Market Forecast
Healthy demand, an expanding foot and ankle market and core trauma innovation led to robust growth in 2024. We project the segment will normalize toward its historical averages in the coming years, with $9.4 billion in sales in 2025 and$10.7 billion by 2028.
Favorable demographics, underserved markets and innovation will drive growth over the next few years.
Exhibit 1: Worldwide Trauma Sales by Year ($millions)
Get More Orthopedic Market Data. Download the Orthopedic Companies Sales Matrix for our most complete and granular numbers. It contains worldwide orthopedic sales for 75 public and private companies by segment from 2016 through 2024.
Here are some of the trauma market dynamics we considered in our forecast:
Demographic Tailwinds. The trauma segment benefits from longer life expectancy increased incidence of diabetes and obesity among potential patients. According to the U.S. Department of Health and Human Services, about 16% of the U.S. population is 65 or older. By 2040, that percentage will increase to 22%. According to the Centers for Disease Control and Prevention (CDC), the prevalence of diagnosed diabetes in the U.S. population increased from 0.9% in 1958 to 10.5% in 2018. Likewise, 2018 data from the CDC showed a staggering 74% of the U.S. adult population was overweight or obese.
Choppy Foot and Ankle Volumes. Surgical volumes are inconsistent in the space. The number of procedures slowed in late 2023 and remained inconsistent throughout much of 2024. We expect quarterly variability in 2025 due to the depletion of backlogged procedures and lower priority placed on foot and ankle compared to other specialties. Still, foot and ankle market sales average out to high-single-digit growth.
Opportunities for Innovation. While the core trauma segment is large and mature, the need for novel solutions remains. X-Bolt’s mechanically reversible PRO-X1 Trochanetic Nail provides a new way to treat patients with osteoporotic hip fractures. In trials, the PRO-X1 had a cut-out rate of 0.8%, less than half of the 2.5% that is typically reported in the literature. Onkos Surgical’s NanoCept Antibacterial Technology, a novel coating applied to implants to help address intraoperative bacterial contamination, could have broad applicability in oncology, trauma and revision surgeries.
Sales by Region
Volume-based procurement (VBP) in China created substantial price cuts for trauma implants in 2023 and has largely shifted off-tender volumes to domestic players. Globalized players that decided to remain in the Chinese market have adjusted their level of investment and expected return.
Several public companies reported international success elsewhere in 2024 and said they’re increasingly looking to new geographic markets to maintain healthy growth rates. Stryker called Europe “a growth engine.” Further, smaller European and Asian companies are targeting the United States and Latin American countries to increase sales.
Exhibit 2: Trauma Sales by Region ($millions)
| Region | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $5,986.3 | $5,622.8 | $363.4 | 6.5% |
| OUS | $3,083.8 | $2,909.5 | $174.3 | 6% |
| EMEA | $1,659.8 | $1,552.9 | $106.9 | 6.9% |
| APAC | $997.7 | $968.4 | $29.3 | 3% |
| ROW | $426.3 | $388.2 | $38.1 | 9.8% |
| Total | $9,070.1 | $8,532.4 | $537.7 | 6.3% |
Exhibit 3: Trauma Market Share by Region ($millions)
Top Companies
The trauma market has two players — Johnson & Johnson MedTech and Stryker — with double-digit market share. Both companies control at least 29% of the trauma market, about four times the nearest competitor.
Zimmer Biomet, Smith+Nephew and Acumed round out the top five players. Combined, this group accounts for 77% of global trauma sales. That percentage increased in early 2025 when Zimmer Biomet agreed to acquire Paragon 28.
Exhibit 4: Top 10 Trauma Players and All Others ($millions)
| Company | FY24 | FY23 | $ Chg | % Chg |
|---|---|---|---|---|
| J&J MedTech | $2,713.1 | $2,651.2 | $61.9 | 2.3% |
| Stryker | $2,625.9 | $2,352.6 | $273.3 | 11.6% |
| Zimmer Biomet | $681.5 | $664.2 | $17.3 | 2.6% |
| Smith+Nephew | $530.4 | $490.0 | $40.4 | 8.3% |
| Acumed | $418.9 | $400.5 | $18.4 | 4.6% |
| Paragon 28 | $215.4 | $186.1 | $29.3 | 15.7% |
| Arthrex | $213.7 | $204.3 | $9.4 | 4.6% |
| Medartis | $213.5 | $195.0 | $18.4 | 9.4% |
| Treace Medical Concepts | $205.6 | $187.1 | $18.5 | 9.9% |
| Skeletal Dynamics | $128.8 | $118.7 | $10.1 | 8.5% |
| All Others | $1,123.3 | $1,082.6 | $40.6 | 3.8% |
| Total | $9,070.1 | $8,532.4 | $537.7 | 6.3% |
Exhibit 5: Trauma Market Share by Company ($millions)
VBP in China and portfolio gaps hampered Johnson & Johnson MedTech’s ability to drive market growth in trauma. In contrast, Stryker’s acquisition of Wright Medical provided the company with an infusion of products and executives that put it on the path to leadership in the trauma segment. Stryker’s largest-ever trauma launch, the Pangea plating system, will reach full commercialization in the second half of 2025 and spur more growth.
In the next tier of companies, Zimmer Biomet took a major step in addressing its trauma strategy with the pending acquisition of fast-growing Paragon 28. Smith+Nephew’s EVOS plating system drove strong sales in 2024, making trauma one of the few orthopedic bright spots for the company.
Among smaller players, Treace Medical faced some headwinds during 2024 but is expanding its portfolio to address a broader range of procedures. Enovis’ foot and ankle business reached the $100 million market in short order, and the company expects it to reach $200 million in the next few years.
Important Developments in the Trauma Market
Under the Radar Highlight. According to Globus Medical’s leadership, the integration of NuVasive Specialty Orthopedics’ trauma products was a highlight of the merger. The products fit with Globus Medical’s strategic goal to address a full range of musculoskeletal treatments. The combined business found increased market penetration and uptake during 2024. Supply constraints offset some growth potential in the fourth quarter, but Globus Medical believes the opportunities for its trauma business have never been stronger.
Orthofix’s Strategic Shift. Orthofix’s hectic 2023 included the integration of SeaSpine and a sudden leadership change. While the combined organization emerged from the year with solid pro forma growth, the company faced questions about its slow-growing trauma business. That business took a significant step forward in 2024, driven by a strategic shift to focus on the U.S. market, which saw sales increase 16% over 2023.
Zimmer Biomet Takes Major Step. Zimmer Biomet struggled to generate the same foot and ankle momentum as its peers. In 2023, the company said foot and ankle sales made up 4% of its S.E.T. category, or around $70 million. The company made a significant move to contend in the space when it entered into a definitive agreement to purchase Paragon 28 for a total enterprise value of $1.2 billion. The deal will boost Zimmer Biomet’s foot and ankle revenue to more than $320 million.
Further Reading
Thanks for visiting! Need more insight on the trauma market? Questions and comments are always welcome. You can reach me by email. Until then, I’ve selected a few posts that give insight into our thinking on the trauma market.
January 30, 2025
,
Mike Evers
March 19, 2025
,
Julie A. Vetalice
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
